VERTEX PHARMACEUTICALS INC / MA reported FY 2026 results: revenue $12.95 billion to $13.1 billion. Guidance reaffirmed.
“Vertex today reiterated full year 2026 financial guidance. Vertex's total revenue guidance of $12.95 billion to $13.1 billion”
VERTEX PHARMACEUTICALS INC / MA — fact timeline
Source-grounded facts extracted from VERTEX PHARMACEUTICALS INC / MA's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
VERTEX PHARMACEUTICALS INC / MA reported Q1 2026 results: revenue $2.99 billion, net income $1.0 billion.
“Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 —”
Suketu Upadhyay departed as Director at VERTEX PHARMACEUTICALS INC / MA.
“Suketu Upadhyay informed the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the "2026 Annual Meeting").”
Duncan J. McKechnie was appointed as Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA.
“the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company”
Charles F. Wagner, Jr. was appointed as Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.
“The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company”
Stuart A. Arbuckle retired as Executive Vice President and Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.
“On February 10, 2025, Vertex Pharmaceuticals Incorporated (the “Company”) announced the retirement of Stuart A. Arbuckle, the Company’s Executive Vice President and Chief Operating Officer, effective on July 1, 2025.”
VERTEX PHARMACEUTICALS INC / MA shareholders rejected Shareholder proposal regarding a report on racial and gender pay gaps at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders did not approve a shareholder proposal regarding a report on racial and gender pay gaps: For Against Abstain Non-Votes 63,865,687 157,637,997 694,435 11,540,149”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Shareholder proposal regarding a special shareholder meeting improvement at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders approved a shareholder proposal regarding a special shareholder meeting improvement: For Against Abstain Non-Votes 160,438,357 61,494,550 265,212 11,540,149”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory approval of 2023 compensation program for named executive officers at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders approved, on an advisory basis, the 2023 compensation program for the Company's named executive officers: For Against Abstain Non-Votes 202,098,575 19,223,784 875,760 11,540,149”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2024 at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: For Against Abstain Non-Votes 229,460,523 3,987,619 290,126 0”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Suketu Upadhyay as director at the 2024-05-15 meeting.
“178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: For Against Abstain Non-Votes 229,460,523 3,987,619 290,126 0 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Nancy Thornberry as director at the 2024-05-15 meeting.
“186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Jennifer Schneider as director at the 2024-05-15 meeting.
“6 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Bruce Sachs as director at the 2024-05-15 meeting.
“,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Diana McKenzie as director at the 2024-05-15 meeting.
“,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Jeffrey Leiden as director at the 2024-05-15 meeting.
“08,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Michel Lagarde as director at the 2024-05-15 meeting.
“gainst Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Reshma Kewalramani as director at the 2024-05-15 meeting.
“nual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Alan Garber as director at the 2024-05-15 meeting.
“as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Lloyd Carney as director at the 2024-05-15 meeting.
“neider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay as directors at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149”
VERTEX PHARMACEUTICALS INC / MA reported full year 2024 results: revenue 10.55 to 10.75 billion. Guidance reaffirmed.
“Vertex today reiterated its full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion.”
VERTEX PHARMACEUTICALS INC / MA reported first quarter ended March 31, 2024 results: revenue 2.69 billion.
“as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2024 Financial Results — Product revenue of $2.69 billion, a 13% i ncrease compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.